The DOI matches its Crossref record; 95 of the 96 references it cites were found in a registry or an index; 1 of the 121 sources its claims cite were checked for support.
p53 at a glance
Open accessAbstract
Since its discovery in 1979, the role of the p53 protein in cancer has been studied intensively (Levine and Oren, 2009). p53 is a crucial tumor suppressor, long-recognized to suppress cancer through the induction of cell-cycle-arrest or apoptosis programs in response to a plethora of different cellular stress signals. Although this model paints a seemingly simple picture, the longer that p53 is studied, the more it confronts researchers with new questions about its functions and mechanisms of action. The tumor-suppressor function of p53 extends beyond the capacity to trigger cell-cycle arrest and apoptosis, and novel activities that impact tumor suppression are perpetually emerging, including the regulation of metabolism, autophagy and the oxidative status of the cell. Moreover, because it acts as a crucial node downstream of diverse stress signals, it is perhaps not surprising that p53 has been recently discovered to have broader roles in physiology and pathology. In this article and its accompanying poster, we outline the basic molecular and cellular functions of p53, describe the intricate network of p53 mediators, and provide insight into the roles of p53 in normal physiology and human disease.Analysis of human cancers reveals a fundamental role for p53 in tumor suppression. More than half of human cancers, of a wide variety of types, harbor p53 (TP53) mutations, and inheritance of a mutant p53 allele predisposes humans to the Li-Fraumeni cancer syndrome (Olivier et al., 2010). Unequivocal confirmation of the crucial role for p53 in tumor suppression was demonstrated by the completely penetrant cancer phenotype of p53-null mice (Kenzelmann Broz and Attardi, 2010). p53 restricts tumor development by serving as a sensor of cellular stress, responding to diverse signals, including DNA damage, hypoxia, oncogene expression, nutrient deprivation and ribosome dysfunction, and limiting the propagation of cells under these adverse conditions (Vousden and Prives, 2009). In metazoans, an ancestral function of p53 is thought to be its ability to trigger programmed cell death (also known as apoptosis) in response to DNA damage, as a measure to preserve the integrity of the germ line (Junttila and Evan, 2009; Lu and Abrams, 2006; Lu et al., 2009). Subsequently, with the evolution of longer-living organisms, p53 is thought to have acquired the ability to respond to oncogenic signals, promoting apoptosis or senescence – a permanent cell-cycle-arrest response – as a safeguard against neoplasia. Thus, in cells exposed to potent stress signals, p53 drives irreversible programs of apoptosis or senescence to cull irreparably damaged or malignant cells, for the ultimate benefit of the organism (Vousden and Prives, 2009). Alternatively, under conditions of low-level stress, p53 elicits protective, pro-survival responses, such as temporary cell-cycle arrest, DNA repair and antioxidant protein production, to maintain genome integrity and viability in cells that sustain limited, reparable damage. These various responses rely on the ability of p53 to function as a transcriptional activator of a panoply of target genes, although transactivation-independent activities ascribed to p53 can also contribute to p53-mediated responses, as highlighted below.Similarly to other transcription factors, p53 has a modular protein domain structure (Joerger and Fersht, 2007; Vousden and Prives, 2009). The N-terminus of p53 comprises two transcriptional activation domains (TADs), TAD1 and TAD2, which span amino acid residues 1-40 and 40-60, respectively. These domains can independently enhance transcription of p53 target genes by recruiting histone-modifying enzymes, components of the basal transcriptional machinery and coactivator complexes, such as STAGA and Mediator (Gamper and Roeder, 2008; Joerger and Fersht, 2007). C-terminal to the transactivation domains, between residues 60-95, lies the proline-rich domain (PRD), which was originally proposed to participate in protein-protein interactions on the basis of the presence of PxxP motifs that resemble Src homology 3 (SH3)-domain-binding regions (Toledo et al., 2006; Toledo et al., 2007). However, a structural function might be the main role of this domain because knock-in mice carrying proline-to-alanine point mutations in the putative protein-protein interaction sites of this domain appear normal, whereas complete domain deletion disrupts p53 tumor-suppressor function. The central core of p53, which spans residues 100-300, comprises the DNA-binding domain that is responsible for sequence-specific binding of the protein to p53 response elements in DNA. Most cancer-associated p53 mutations are missense mutations in this domain and incapacitate DNA binding, illuminating the key importance of DNA binding for p53-mediated tumor suppression. Tumor-derived p53 mutations either alter residues that are essential for direct contact with p53 response elements (contact mutants) or impair proper folding of
Overview
CoChat Summary
TL;DR
This review summarizes p53 as a central stress-sensing tumor suppressor, covering its protein domains, transcriptional and cytoplasmic functions, regulation by MDM2/MDMX, and broader roles in physiology and disease. It emphasizes that p53 outcomes are highly context-dependent and that its biology is more complex than the canonical cell-cycle-arrest/apoptosis model.
Key findings
- p53 is mutated in more than half of human cancers of many types; inherited mutant p53 predisposes to Li-Fraumeni syndrome, and p53-null mice have a completely penetrant cancer phenotype.
- p53 has a modular domain structure: TAD1 (residues 1–40), TAD2 (40–60), proline-rich domain (60–95), DNA-binding core (100–300), tetramerization domain (325–356), and C-terminal basic domain (363–393). The six most common cancer hotspot residues are R175, G245, R248, R249, R273 and R282.
- p53 binds response elements as a tetramer, classically two half sites of RRRCWWGYYY separated by 0–13 bp. Severe stress drives apoptosis or senescence; low-level stress promotes temporary arrest, DNA repair and antioxidant responses. p53 also has cytoplasmic roles in apoptosis and autophagy, metabolic effects, and non-cell-autonomous tumor-suppressive effects.
- MDM2 and MDMX regulate p53 levels and activity. Mdm2-null mice show very early embryonic lethality that is completely rescued by p53 loss; Mdmx-null mice show p53-dependent embryonic lethality later in embryogenesis. p53 also activates MDM2 transcription, forming a negative-feedback loop.
Methods
- Narrative review article with an accompanying poster; no primary experimental design, sample or new data are reported.
- Synthesizes published literature on p53 molecular and cellular functions, its regulators, and its roles in normal physiology and human disease.
- No systematic review, meta-analysis or quantitative synthesis methods are stated.
Limitations
- The authors state that capturing the complete complexity of p53 function is beyond the scope of the article; they note omitted topics including post-translational modifications, p53 polymorphisms, p53 isoforms, and p63/p73 family interplay.
- The text highlights unresolved or controversial areas, including pro-aging versus anti-aging roles of p53 in different mouse models, the dual role of autophagy in tumor suppression, uncertainty about the full importance of the MDMX-MDM2 interaction, complexity of C-terminal lysine modifications, and unknown significance of p53 isoforms.
- Evident from the text: as a narrative review, it does not provide a systematic search strategy, quantitative synthesis, or primary data, and many conclusions rely on cited reviews and model systems.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
1 Valid · 0 Not valid · 68 Not checked · 34 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“exciting recent findings have shown that reactivation of p53 expression in mouse models induces tumor regression (Martins et al., 2006; Ventura et al., 2007; Xue et al., 2007).”
What the sources say
- Not checked yetcites Martins et al., 2006 source
- Not checked yetcites Ventura et al., 2007 source
- Supportedcites Xue et al., 2007 source
Our copy of Xue et al. (2007) states directly that reactivating endogenous p53 in p53-deficient tumours produces complete tumour regression in vivo: the Abstract reports 'even brief reactivation of endogenous p53 in p53-deficient tumours can produce complete tumour regressions', and the results describe hepatocarcinomas involuting to near-undetectable levels within 12 days of Dox-mediated p53 restoration (p. 1, Fig. 1b) and regressing after only 4 days of Dox (p. 2, Fig. 1e), including in a subcutaneous setting and in tumours co-expressing activated Akt or oncogenic K-ras. The mechanism (senescence plus innate immune clearance) is additional detail not required by the citing sentence, which is offered as one of three mouse-model citations for p53 reactivation-induced regression. (LLM, conf=0.95)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In response to sustained or severe stress signals, p53 drives irreversible apoptosis or senescence programs.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Additionally, a major component of repression probably occurs through indirect mechanisms, such as by p53-dependent activation of microRNAs or lincRNAs that repress gene expression (Guttman et al., 2009; He et al., 2007; Menendez et al., 2009; Riley et al., 2008).”
What the sources say
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“p53 also has a complex role in regulating autophagy.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The central core of p53, which spans residues 100-300, comprises the DNA-binding domain that is responsible for sequence-specific binding of the protein to p53 response elements in DNA.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
58 more claims
Create a free account to see all 103 claims and to verify the 108 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 9
Citations
Cites
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals
Guttman, M., Amit, I., Garber, M., French, C., Lin, M. F., Feldser, D., Huarte, M., Zuk, O., Carey, B. W., Cassady, J. P., et al. (2009) · Nature · doi:10.1038/nature07672 · Cited by 4,098
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“More than half of human cancers, of a wide variety of types, harbor p53 (TP53) mutations, and inheritance of a mutant p53 allele predisposes humans to the Li-Fraumeni cancer syndrome (Olivier et al., 2010).”
BackgroundSenescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Indeed, exciting recent findings have shown that reactivation of p53 expression in mouse models induces tumor regression (Martins et al., 2006; Ventura et al., 2007; Xue et al., 2007).”
Backgroundp53 Has a Direct Apoptogenic Role at the Mitochondria
Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., & Moll, U. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00050-9 · Cited by 1,777
Cited by
Items 101–200 of 404
p53 signaling pathway polymorphisms associated to recurrent pregnancy loss
Fraga, L. R., Dutra, C. G., Boquett, J. A., Vianna, F. S. L., Gonçalves, R. O., Paskulin, D. D., Costa, O. L. N., Ashton‐Prolla, P., Sanseverino, M. T. V., & Schüler‐Faccini, L. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3036-6 · Cited by 42
Pelletier, J., Dayan, F., Durivault, J., Ilc, K., Pécou, E., Pouysségur, J., & Mazure, N. M. (2011) · Oncogene · doi:10.1038/onc.2011.471 · Cited by 41
Effects of different extracts of curcumin on TPC1 papillary thyroid cancer cell line
Perna, A., Luca, A. D., Adelfi, L., Pasquale, T., Varriale, B., & Esposito, T. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2125-9 · Cited by 41
Non-coding RNAs, guardians of the p53 galaxy
Chen, S., Thorne, R. F., Zhang, X. D., Wu, M., & Liu, L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.002 · Cited by 41
IPMK: A Versatile Regulator of Nuclear Signaling Events
Kim, E., Beon, J., Lee, S., Park, J., & Kim, S. (2016) · Advances in Biological Regulation · doi:10.1016/j.jbior.2015.11.005 · Cited by 39
Battle Against Cancer: An Everlasting Saga of p53
Hao, Q., & Cho, W. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151222109 · Cited by 48
Wang, W., Chen, K., Su, Y., Zhang, J., Li, M., & Zhou, J. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.7b01549 · Cited by 39
Chemical Variations on the p53 Reactivation Theme
Ribeiro, C. J. A., Rodrigues, C. M. P., Moreira, R., & Santos, M. M. M. (2016) · Pharmaceuticals · doi:10.3390/ph9020025 · Cited by 37
Pan, L.-Z., Ahn, D., Sharif, T., Clements, D. R., Gujar, S. A., & Lee, P. W. K. (2014) · Cell Cycle · doi:10.4161/cc.28128 · Cited by 37
Fleury, H., Communal, L., Carmona, E., Portelance, L., Arcand, S. L., Rahimi, K., Tonin, P. N., Provencher, D. M., & Mes‐Masson, A. (2015) · Genes & Cancer · doi:10.18632/genesandcancer.76 · Cited by 37
Eleftheriadis, T., Pissas, G., Antoniadi, G., Liakopoulos, V., & Stefanidis, I. (2018) · Biology · doi:10.3390/biology7040048 · Cited by 37
Mitochondrial transplantation strategies in multifaceted induction of cancer cell death
Cruz‐Gregorio, A., Aranda‐Rivera, A. K., Amador‐Martínez, I., & Maycotte, P. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122098 · Cited by 36
The HERC2 ubiquitin ligase is essential for embryonic development and regulates motor coordination
Cubillos‐Rojas, M., Schneider, T., Hadjebi, O., Pedrazza, L., de Oliveira, J. R., Vives, F. L., Guénet, J., Duran, J., de Anta, J. M., Alcántara, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11270 · Cited by 36
Trino, S., Luca, L. D., Laurenzana, I., Caivano, A., Vecchio, L. D., Martinelli, G., & Musto, P. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00491 · Cited by 36
Effects of curcumin and its adjuvant on TPC1 thyroid cell line
Esposito, T., Lucariello, A., Hay, E., Contieri, M., Pasquale, T., Varriale, B., Guerra, G., Luca, A. D., & Perna, A. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.03.031 · Cited by 36
Mondal, P., Gadad, S. S., Adhikari, S., Ramos, E., Sen, S., Prasad, P., & Das, C. (2021) · The FASEB Journal · doi:10.1096/fj.202002486rr · Cited by 37
Ribeiro, E. S., Monteiro, A. P. A., Bisinotto, R. S., de Lima, F. S., Greco, L. F., Ealy, A. D., Thatcher, W. W., & Santos, J. E. P. (2016) · Journal of Dairy Science · doi:10.3168/jds.2015-10315 · Cited by 36
Guo, Q., Lan, F., Xu, Y., Zhu, X., Wu, Y., & Zhang, Q. (2018) · Oncology Letters · doi:10.3892/ol.2018.8767 · Cited by 35
Targeted OMA1 therapies for cancer
Alavi, M. V. (2019) · International Journal of Cancer · doi:10.1002/ijc.32177 · Cited by 35
van Bergeijk, P., Heimiller, J., Uyetake, L., & Su, T. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036539 · Cited by 36
The Expanding Significance of Inositol Polyphosphate Multikinase as a Signaling Hub
Kim, E., Ahn, H., Kim, M., Lee, H., & Kim, S. (2017) · Molecules and Cells · doi:10.14348/molcells.2017.0066 · Cited by 36
Salvador-Warts-Hippo Pathway in a Developmental Checkpoint Monitoring Helix-Loop-Helix Proteins
Wang, L.-H., & Baker, N. E. (2015) · Developmental Cell · doi:10.1016/j.devcel.2014.12.002 · Cited by 34
Buizza, L., Prandelli, C., Bonini, S. A., Delbarba, A., Cenini, G., Lanni, C., Buoso, E., Racchi, M., Govoni, S. M., Memo, M., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.13 · Cited by 34
Gostissa, M., Bianco, J. M., Malkin, D. J., Kutok, J. L., Rodig, S. J., Morse, H. C., Bassing, C. H., & Alt, F. W. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222570110 · Cited by 34
The Complex Interaction between P53 and miRNAs Joins New Awareness in Physiological Stress Responses
Capaccia, C., Diverio, S., Zampini, D., & Guelfi, G. (2022) · Cells · doi:10.3390/cells11101631 · Cited by 34
Kundu, S., Kim, T. H., Yoon, J. H., Shin, H.-S., Lee, J., Jung, J. H., & Kim, H. S. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2659 · Cited by 33
Raimondi, I., Ciribilli, Y., Monti, P., Bisio, A., Pollegioni, L., Fronza, G., Inga, A., & Campomenosi, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069152 · Cited by 33
Wang, W. J., Luo, J., Liang, Y., & Li, X. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4867 · Cited by 32
The Effect of Arabic Gum on Renal Function in Reversible Unilateral Ureteric Obstruction
Hammad, F. T., Al‐Salam, S., Nemmar, A., Ali, M. A., & Lubbad, L. (2019) · Biomolecules · doi:10.3390/biom9010025 · Cited by 32
Sinha, S., Dwivedi, T. R., Yengkhom, R., Bheemsetty, V. A., Abe, T., Kiyonari, H., VijayRaghavan, K., & Inamdar, M. S. (2019) · Blood · doi:10.1182/blood.2019000530 · Cited by 32
Myc-Induced Liver Tumors in Transgenic Zebrafish Can Regress in tp53 Null Mutation
Sun, L., Nguyễn, A. T., Spitsbergen, J. M., & Gong, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117249 · Cited by 31
Interaction of p53 with prolyl isomerases: Healthy and unhealthy relationships
Mantovani, F., Zannini, A., Rustighi, A., & Sal, G. D. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.01.013 · Cited by 31
Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis
Iwahashi, N., Ikezaki, M., Komohara, Y., Fujiwara, Y., Noguchi, T., Nishioka, K., Sakai, K., Nishio, K., Ueda, M., Ihara, Y., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac128 · Cited by 31
ISG15 Deficiency Enhances HIV-1 Infection by Accumulating Misfolded p53
Kuffour, E. O., König, R., Häussinger, D., Schulz, W. A., & Münk, C. (2019) · mBio · doi:10.1128/mbio.01342-19 · Cited by 31
Shen, Y., Xu, K., Yuan, Z., Guo, J., Zhao, H., Zhang, X., Zhao, L., Qing, Y., Li, H., Pan, W., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1327-0 · Cited by 35
HOPS/TMUB1 retains p53 in the cytoplasm and sustains p53‐dependent mitochondrial apoptosis
Castelli, M., Piobbico, D., Chiacchiaretta, M., Brunacci, C., Pieroni, S., Bartoli, D., Gargaro, M., Fallarino, F., Puccetti, P., Soddu, S., et al. (2019) · EMBO Reports · doi:10.15252/embr.201948073 · Cited by 30
Shatz, M., Shats, I., Menendez, D., & Resnick, M. A. (2015) · Oncotarget · doi:10.18632/oncotarget.4435 · Cited by 29
ADP-ribosylation and intracellular traffic: an emerging role for PARP enzymes
Grimaldi, G., & Corda, D. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180416 · Cited by 29
Neitzel, C., Seiwert, N., Göder, A., Diehl, E., Weber, C., Nagel, G., Stroh, S., Rasenberger, B., Christmann, M., & Fahrer, J. (2019) · Cells · doi:10.3390/cells8080794 · Cited by 29
Elkady, A. I., Hussein, R. A. E. H., & Abuzinadah, O. A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15275 · Cited by 28
Eleftheriadis, T., Pissas, G., Antoniadi, G., Tsogka, K., Sounidaki, M., Liakopoulos, V., & Stefanidis, I. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4595 · Cited by 28
Guo, H., Fu, X., Li, N., Lin, Q., Liu, L., & Shu-qin, W. (2016) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2016.03.003 · Cited by 28
Defenses against Pro-oxidant Forces - Maintenance of Cellular and Genomic Integrity and Longevity
Murray, D. L., Mirzayans, R., & McBride, W. H. (2018) · Radiation Research · doi:10.1667/rr15101.1 · Cited by 28
Sivakumaran, N., Samarakoon, S. R., Adhikari, A., Ediriweera, M. K., Tennekoon, K. H., Malavige, N., Thabrew, I., & Shrestha, R. L. (2018) · BioMed Research International · doi:10.1155/2018/3171348 · Cited by 27
Identification of universal and cell-type specific p53 DNA binding
Hafner, A., Kublo, L., Tsabar, M., Lahav, G., & Stewart-Ornstein, J. (2020) · BMC Molecular and Cell Biology · doi:10.1186/s12860-020-00251-8 · Cited by 27
Lim, M., Ahn, J., Han, Y., Yu, C., Kim, M., Lee, S., Lim, D., & Song, J. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.04.022 · Cited by 26
Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma
Léveillé, E., & Johnson, N. A. (2021) · Cancers · doi:10.3390/cancers13092167 · Cited by 26
An indirect role for ASPP1 in limiting p53‐dependent p21 expression and cellular senescence
Vigneron, A. M., & Vousden, K. H. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.402 · Cited by 26
Elkady, A. I., Hussein, R. A. E. H., & Abuzinadah, O. A. (2014) · BioMed Research International · doi:10.1155/2014/260210 · Cited by 26
RetractedTumor Suppression: p53 Alters Immune Surveillance to Restrain Liver Cancer
Raj, N., & Attardi, L. D. (2013) · Current Biology · doi:10.1016/j.cub.2013.04.076 · Cited by 26
Self-citationHallberg, I., Persson, S., Olovsson, M. H., Moberg, M., Ranefall, P., Laskowski, D., Damdimopoulou, P., Sirard, M., Rüegg, J., & Sjunnesson, Y. C. B. (2022) · Reproductive Toxicology · doi:10.1016/j.reprotox.2022.02.004 · Cited by 25
MDM2-Mediated Degradation of p14ARF: A Novel Mechanism to Control ARF Levels in Cancer Cells
Vivo, M., Matarese, M., Sepe, M., Martino, R. D., Festa, L., Calabrò, V., Mantia, G. L., & Pollice, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117252 · Cited by 25
Guilty as CHARGED: p53's expanding role in disease
Nostrand, J. L. V., & Attardi, L. D. (2014) · Cell Cycle · doi:10.4161/15384101.2014.987627 · Cited by 25
Self-citationMahalakshmi, R., Pallikonda, H. A., & Mahadevan, V. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1302820 · Cited by 25
Synthesis and Antiproliferative Activity of Novel Heterocyclic Glycyrrhetinic Acid Derivatives
Alho, D. P. S., Salvador, J. A. R., Cascante, M., & Marín, S. (2019) · Molecules · doi:10.3390/molecules24040766 · Cited by 25
DNA damage induced activation of Cygb stabilizes p53 and mediates G1 arrest
John, R., Chand, V., Chakraborty, S., Jaiswal, N., & Nag, A. (2014) · DNA repair · doi:10.1016/j.dnarep.2014.09.003 · Cited by 24
Eleftheriadis, T., Pissas, G., Antoniadi, G., Liakopoulos, V., & Stefanidis, I. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2763 · Cited by 24
Relevance of TP53 for CLL diagnostics
Catherwood, M. A., de Castro, D. G., Donaldson, D. M., Clifford, R. M., Mills, K., & Thornton, P. D. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205622 · Cited by 24
Xing, Y., & Li, L. (2019) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2019.01.013 · Cited by 24
RetractedImpaired Mitochondrial Metabolism and Mammary Carcinogenesis
Yadava, N., Schneider, S. S., Jerry, D. J., & Kim, C. G. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9271-3 · Cited by 25
Cubillos‐Rojas, M., Schneider, T., Bartrons, R., Ventura, F., & Rosa, J. L. (2017) · Oncotarget · doi:10.18632/oncotarget.18699 · Cited by 23
Halaby, M., Hakem, A., Li, L., Ghamrasni, S. E., Venkatesan, S., Hande, M. P., Sanchez, O. H., & Hakem, R. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003259 · Cited by 23
Cui, C., Jia, Q., Deng, Q., Chen, R., Zhai, D., & Yu, J. (2016) · BioMed Research International · doi:10.1155/2016/1804137 · Cited by 23
p53/p73 Protein Network in Colorectal Cancer and Other Human Malignancies
Horvat, A., Tadijan, A., Vlašić, I., & Slade, N. (2021) · Cancers · doi:10.3390/cancers13122885 · Cited by 22
Routes of Albumin Overload Toxicity in Renal Tubular Epithelial Cells
Eleftheriadis, T., Pissas, G., Golfinopoulos, S., Efthymiadi, M., Poulianiti, C., Konsta, M. A. P., Liakopoulos, V., & Stefanidis, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119640 · Cited by 21
RNF125 is a Ubiquitin-Protein Ligase that Promotes p53 Degradation
Yang, L., Zhou, B., Li, X., Lu, Z., Li, W., Huo, X., & Miao, Z. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000369691 · Cited by 21
Dynamic Changes in Circulating Tumor DNA During Chemoradiation for Locally Advanced Lung Cancer
Corradetti, M. N., Torok, J. A., Hatch, A. J., Xanthopoulos, E. P., Lafata, K. J., Jacobs, C. D., Rushing, C. N., Calaway, J. D., Jones, G., Kelsey, C. R., et al. (2019) · Advances in Radiation Oncology · doi:10.1016/j.adro.2019.05.004 · Cited by 21
Delay in development and behavioural abnormalities in the absence of p53 in zebrafish
Elabd, S., Jabeen, N. A., Gerber, V., Peravali, R., Bourdon, J., Kancherla, S., Vallone, D., & Blattner, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220069 · Cited by 21
Association of p53 Arg72Pro polymorphism with bladder cancer: A meta-analysis
Yang, Z., Nie, S., Zhu, H., Wu, X., Jia, S., Luo, Y., & Tang, W. (2012) · Gene · doi:10.1016/j.gene.2012.09.085 · Cited by 21
RB goes mitochondrialPreprint
Attardi, L. D., & Sage, J. (2013) · Genes & Development · doi:10.1101/gad.219451.113 · Cited by 21
Self-citationZhao, L., Zhao, X., Wu, X., & Tang, W. (2013) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2013.0103 · Cited by 20
Recent developments in autophagy-targeted therapies in cancer
Jogalekar, M. P., Veerabathini, A., & Gangadaran, P. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220966545 · Cited by 20
Vehniäinen, E., Vähäkangas, K., & Oikari, A. (2011) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2011.01058.x · Cited by 20
Eleftheriadis, T., Pissas, G., Golfinopoulos, S., Efthymiadi, M., Liakopoulos, V., & Stefanidis, I. (2022) · Biomolecules · doi:10.3390/biom12101415 · Cited by 19
Mimicking p14ARF Phosphorylation Influences Its Ability to Restrain Cell Proliferation
Vivo, M., Ranieri, M., Sansone, F., Santoriello, C., Calogero, R., Calabrò, V., Pollice, A., & Mantia, G. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053631 · Cited by 19
p53 activates circASCC3 to repress R-loops and enhance resistance to chemotherapy
Cao, M., Gan, Y., Huang, Y., Tong, J., Chen, X., Chen, Y., Chen, B., Huang, R., Xie, B., Deng, J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2415869122 · Cited by 18
Melanson, B. D., Cabrita, M. A., Bose, R., Hamill, J. D., Pan, E., Brochu, C., Marcellus, K. A., Zhao, T. T., Holčík, M., & McKay, B. C. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt279 · Cited by 18
Villicaña, C., Cruz‐Becerra, G., & Zurita, M. (2013) · Journal of Cell Science · doi:10.1242/jcs.122721 · Cited by 18
Bai, B., Yang, Y., Wei, J., Zheng, Q., Wang, M., Chang, A. K., & Ying, X. (2022) · Frontiers in Marine Science · doi:10.3389/fmars.2022.1080516 · Cited by 17
Metu, C. L. N., Sutihar, S. K., Sohel, M., Zohora, F., Hasan, A., Miah, M. T., Kar, T. R., Hossain, M. A., & Rahman, M. H. (2023) · Cancer Reports · doi:10.1002/cnr2.1889 · Cited by 17
Jalili, C., shamsi, R. R., Amiri, B., Kakebaraie, S., Jalili, F., & Nasta, T. Z. (2024) · Toxicology · doi:10.1016/j.tox.2024.153773 · Cited by 17
Guo, H., Fu, X., Lin, Q., Liu, L., Liang, H., Huang, Z., Li, N., & Su, J. (2017) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2017.09.039 · Cited by 17
Simkin, M., Abdalla, M. A. K., El-Mogy, M. M., & Haj-Ahmad, Y. (2012) · Epigenomics · doi:10.2217/epi.12.24 · Cited by 17
Permata, T. S., & Bustamam, A. (2015) · International Conference on Advanced Computer Science and Information Systems · doi:10.1109/icacsis.2015.7415177 · Cited by 17
Melatonin-Induced Oncostasis, Mechanisms and Clinical Relevance
Cardinali, D. P., & Escames, G. (2016) · Journal of Integrative Oncology · doi:10.4172/2329-6771.s1-006 · Cited by 17
ATM and P53 differentially regulate pancreatic beta cell survival in Ins1E cells
Uhlemeyer, C., Müller, N., Grieß, K., Wessel, C., Schlegel, C., Kuboth, J., & Belgardt, B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237669 · Cited by 18
Downey, J., Randolph, H. E., Pernet, E., Tran, K. A., Khader, S. A., King, I. L., Barreiro, L. B., & Divangahi, M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110974 · Cited by 16
Aging, longevity, and the role of environmental stressors: a focus on wildfire smoke and air quality
Scieszka, D. P., Bolt, A. M., McCormick, M. A., Brigman, J. L., & Campen, M. J. (2023) · Frontiers in Toxicology · doi:10.3389/ftox.2023.1267667 · Cited by 16
Marwah, H., & Dewangan, H. K. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096366956250314043513 · Cited by 16
Wei, S., Schell, J. R., Qian, W., Silguero, M., Baseviciene, A., Chen, W. H., Trevino, R., Chocrón, E. S., Ogle, M. M., Varmazyad, M., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116026 · Cited by 16
Patil, V. S., & Mahalingam, K. (2018) · Gene · doi:10.1016/j.gene.2018.10.069 · Cited by 16
The Janus Face of p53-Targeting Ubiquitin Ligases
Hao, Q., Chen, Y., & Zhou, X. Y. (2020) · Cells · doi:10.3390/cells9071656 · Cited by 16
Eleftheriadis, T., Pissas, G., Filippidis, G., Liakopoulos, V., & Stefanidis, I. (2021) · Biomolecules · doi:10.3390/biom11101522 · Cited by 16
Haas, M., Wirachowski, K., Thibol, L., Küpper, J., Schrenk, D., & Fahrer, J. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03482-8 · Cited by 16
Characterization of the tilapia p53 gene and its role in chemical-induced apoptosis
Mai, W., Liu, P., & Wang, W. (2012) · Biotechnology Letters · doi:10.1007/s10529-012-0980-x · Cited by 16
Chen, L., Li, Y., Li, X., Lü, Z., Zheng, Q., & Liu, Q. (2018) · The Journal of Antibiotics · doi:10.1038/s41429-018-0104-5 · Cited by 16
Effect of Soy Isoflavone on Prostate Cancer Cell Apoptosis Through Inhibition of STAT3, ERK, and AKT
Lee, Y., Lee, C., Choi, D., Lee, Y., & Lee, S. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46110743 · Cited by 15
An Unbiased Linkage Approach Reveals That the p53 Pathway Is Coupled to NK Cell Maturation
Collin, R., St-Pierre, C., Guilbault, L., Mullins‐Dansereau, V., Policheni, A. N., Guimont‐Desrochers, F., Pelletier, A., Gray, D. H. D., Drobetsky, E. A., Perreault, C., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1600789 · Cited by 15
Sui, Y., Wu, T., Li, F., Wang, F., Cai, Y., & Jin, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092095 · Cited by 15
Sinha, V. C., Qin, L. F., & Li, Y. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0481-t · Cited by 15
Metadata
- Authors
- Brady, C. A., & Attardi, L. D.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Attardi, Laura D.
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2010-08-01
- Volume
- 123
- Issue
- 15
- Pages
- 2527-2532
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- PMC
- PMC2912460
- OpenAlex
- W2170622332
- Cited by
- 403
- References
- 96
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 19 · 2023: 28 · 2022: 17 · 2021: 24 · 2020: 29 · 2019: 39 · 2018: 32 · 2017: 28 · 2016: 22 · 2015: 27 · 2014: 33 · 2013: 26 · 2012: 27
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Locations
- Journal of Cell Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, tumor suppressor, TP53 mutation, Li-Fraumeni syndrome, cell cycle arrest, apoptosis, cellular stress response, DNA damage, hypoxia, oncogene-induced senescence, autophagy, cellular metabolism, oxidative stress, p53-null mice, cancer susceptibility
- MeSH terms
- Animals, Autophagy, Cytoplasm, Humans, Neoplasms, Transcriptional Activation, Tumor Suppressor Protein p53, Apoptosis, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-15, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-15 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.